We speculate that the ER modulation is necessary for the early-phase TGFβ signaling to act as a tumor suppressor at an early phase of TGFβ1 treatment, thus the name “early-TGFB1 signature.” In our data, the early-TGFβ signature has 6 ER-MRTPs in the survival sub-network (Fig. 4C). The gene discussed is TGFB1; the disease is neoplasm.